Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding Ltd (OP: RHHVF )

321.07 -3.28 (-1.01%)
Streaming Delayed Price Updated: 3:59 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 143
Open 324.56
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 324.35
Today's Range 321.07 - 324.79
52wk Range 233.12 - 332.73
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases. 
Via MarketBeat
Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M
Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries. 
Via Benzinga
Exposures COVID-19

Performance

YTD
+12.44%
+12.44%
1 Month
+11.79%
+11.79%
3 Month
+29.34%
+29.34%
6 Month
+26.95%
+26.95%
1 Year
+6.98%
+6.98%

More News

Read More
Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial
Via Benzinga
Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation
Via Benzinga
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
Via Benzinga
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
Via Benzinga
Exposures Product Safety
Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products
Via Benzinga
Exposures COVID-19
What's Going On Cancer Player Monte Rosa Therapeutics Stock Today?
Via Benzinga
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
Via Benzinga
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
Via Benzinga
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
Via Benzinga
Exposures COVID-19
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
Via Benzinga
Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer
Via Benzinga
Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time
Via Benzinga
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
Via Benzinga
Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study
Via Benzinga
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
Via Benzinga
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
Via Benzinga
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
Via Benzinga
Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy
Via Benzinga
Nvidia Invested $50 million into This AI Drug Discovery Biotech
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal
Via Benzinga
Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion
Via Benzinga
Agilent Technologies Stock: Ready to Rise off the Floor
Via MarketBeat
DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth
Via MarketBeat
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.